prodchem
Sep 10, 2026
The American Chemistry Council expects US industrial production to rise 1.3% in 2026, offering a modest positive signal for chemical demand after several years of weak manufacturing activity. The ACC also reports that pharmaceuticals are among the US end-use industries expected to grow this year, while specialty chemicals supporting healthcare applications should continue to expand.
For pharmaceutical-adjacent chemical producers, the forecast points to a market that is improving rather than accelerating sharply. Demand for specialty chemicals and intermediates can benefit from stronger manufacturing activity, but buyers still face uneven conditions across end-use sectors.
For procurement teams, the key issue is how this industrial recovery translates into chemical availability, supplier utilization, lead times and pricing. A moderate production increase can support demand without necessarily creating broad-based shortages.
The ACC's latest mid-year outlook places US industrial production growth at 1.3% for 2026. The organization says manufacturing activity has shown signs of expansion after a prolonged period of weakness, although growth remains uneven across different customer industries.
The forecast matters to chemical buyers because more than 80% of basic and specialty chemicals are purchased directly by the industrial sector, according to the ACC. As manufacturing output improves, chemical consumption can strengthen across the industries that use these materials as feedstocks, processing aids or formulation inputs.
However, the 1.3% figure should be viewed as modest growth rather than a rapid industrial expansion. Procurement teams should expect demand to improve selectively rather than rise equally across every chemical category.
The ACC expects only 12 of the 20 key chemistry-consuming end-use industries it tracks to expand in 2026. Pharmaceuticals, semiconductors, computers, electrical equipment, aircraft and oil and gas are among the sectors showing stronger prospects.
Pharmaceutical manufacturing creates demand for a wide range of chemical inputs beyond active pharmaceutical ingredients. Solvents, intermediates, polymers, glycols and other specialty materials support manufacturing processes across the pharmaceutical value chain.
The ACC specifically identifies pharmaceuticals as a growing US end-use industry in 2026. Its outlook also says specialty chemicals supporting healthcare will continue to expand, creating a more favorable environment for chemical suppliers serving pharmaceutical applications.
This creates several potential demand channels:
Chemical intermediates: Greater pharmaceutical production can increase requirements for materials used at different stages of chemical synthesis.
Specialty chemicals: Healthcare-related manufacturing can support demand for higher-value chemical products with specific technical requirements.
Process chemicals: Pharmaceutical facilities require solvents and other materials for synthesis, purification and processing.
Industrial support materials: Growth in manufacturing can also increase demand for chemicals used in cleaning, water treatment, coatings and equipment maintenance.
The effect will vary by product. Buyers should therefore avoid assuming that every pharmaceutical-related chemical will experience the same demand increase.
The broader specialty chemical picture remains more complicated than the pharmaceutical signal alone suggests. The ACC expects overall US chemical output volumes to rise only 0.5% in 2026, with basic and agricultural chemicals contributing gains while specialty chemical output is expected to decline slightly by 0.3%.
That apparent contradiction is important for procurement managers. A growing pharmaceutical market can support selected specialty chemical categories even when the broader specialty segment remains under pressure.
The ACC expects specialty chemicals supporting semiconductors, data centers and healthcare to continue expanding. This suggests that chemical demand increasingly depends on the performance of specific high-growth customer markets rather than a uniform manufacturing recovery.
For traders and distributors, product-level demand analysis may therefore provide more useful guidance than relying solely on the overall chemical production forecast.
Moderate industrial growth can create opportunities for chemical suppliers that serve expanding manufacturing segments. Pharmaceutical-related chemicals could benefit if manufacturers increase production schedules and replenish inventories after earlier periods of cautious purchasing.
Procurement teams should pay particular attention to products where demand is closely connected to pharmaceutical production volumes. These materials may experience tighter availability sooner than chemicals serving weaker industrial sectors.
Several factors can influence the opportunity:
Production utilization: Higher plant utilization can increase raw material consumption and improve supplier order books.
Inventory rebuilding: Manufacturers may increase purchases after periods of inventory reduction, creating temporary demand beyond underlying production growth.
Capacity constraints: If a specialized chemical has limited global production capacity, even modest demand growth can affect lead times.
Qualification requirements: Pharmaceutical buyers often cannot switch suppliers quickly, which can amplify demand for qualified sources.
For chemical traders, these conditions make supplier relationships and inventory visibility particularly important.
A 1.3% increase in industrial production does not automatically translate into higher prices for every chemical. Supply conditions remain equally important.
If chemical producers have sufficient spare capacity, higher demand can be absorbed without significant price pressure. If production remains constrained or suppliers reduce capacity, even modest demand growth can tighten selected markets.
The ACC's Q2 2026 Chemical Manufacturing Economic Sentiment Index provides additional evidence of improving activity. The production index reached its highest level since the survey began in early 2023, while the major customer demand index also reached its highest level since Q1 2024.
These indicators suggest that chemical manufacturers are seeing stronger activity in parts of the market. Procurement teams should watch whether improving orders translate into sustained increases in production and capacity utilization.
The current outlook creates a potentially favorable environment for traders that can connect international supply with US industrial demand. Pharmaceutical-adjacent buyers may value reliable sourcing more highly if demand continues to strengthen in selected chemical categories.
Importers should assess suppliers based on more than their quoted unit price. Delivery reliability, production capacity, regulatory documentation and the ability to maintain consistent specifications can become increasingly important as demand improves.
Useful questions for buyers include:
Can the supplier support higher order volumes if demand increases?
Does the producer have sufficient production capacity?
What is the normal lead time for repeat orders?
Are alternative origins available?
Can the supplier provide consistent quality documentation?
How exposed is the product to freight or feedstock cost changes?
These questions can help buyers distinguish between suppliers that can support long-term procurement needs and those suited only to spot purchases.
One of the biggest procurement mistakes would be to interpret the ACC forecast as a signal that all chemical markets will tighten. The forecast describes a moderate overall industrial recovery with significant variation between sectors.
The ACC expects US chemical output itself to increase only 0.5% in 2026. Within that figure, specialty chemical output is projected to decline slightly, even as healthcare-related specialty chemicals continue to expand.
This distinction gives buyers a reason to remain selective.
Products connected to pharmaceutical manufacturing may see healthier demand than materials linked to weaker end-use markets. At the same time, established suppliers may retain adequate capacity for many products, limiting the potential for dramatic price movements.
Procurement strategies should therefore focus on individual product fundamentals rather than broad market assumptions.
Pharmaceutical companies often operate under strict production and quality requirements. A change in chemical demand can therefore have a different effect in this sector compared with conventional industrial manufacturing.
A manufacturer may need to qualify a new chemical supplier before placing commercial orders. Documentation, testing and regulatory requirements can extend the time required to switch sources.
This makes demand forecasting especially valuable. Buyers that anticipate higher production requirements can discuss volume plans with suppliers earlier and reduce the risk of last-minute purchasing.
For critical chemicals, procurement teams can consider:
Sharing realistic demand forecasts with strategic suppliers.
Establishing framework agreements for recurring requirements.
Maintaining qualified secondary sources where practical.
Reviewing safety-stock levels for long-lead-time materials.
Tracking supplier capacity and delivery performance.
Comparing domestic and international sourcing options.
The objective is not to overstock. It is to ensure that procurement decisions reflect the possibility of modestly stronger demand.
The US industrial outlook is improving, but global chemical markets remain exposed to significant uncertainties. The ACC expects global chemical production to grow only 0.5% in 2026, citing disruptions affecting chemical production in the Middle East, parts of Asia and Europe.
This global backdrop matters for US buyers that depend on imported specialty chemicals and intermediates. A stronger domestic manufacturing environment can increase demand at the same time that international supply faces production or logistics constraints.
That combination can create uneven market conditions. Some products may remain readily available while others experience longer lead times or higher landed costs.
Importers should therefore monitor both US demand indicators and international production conditions when planning chemical purchases.
Procurement teams do not need to make aggressive purchasing decisions based on a 1.3% industrial production forecast. A better approach involves targeted preparation around products with clear exposure to growing end-use markets.
Start with demand mapping. Identify which purchased chemicals are directly or indirectly linked to pharmaceuticals, healthcare manufacturing and other sectors that the ACC expects to expand.
Then assess supply flexibility. Products with multiple qualified suppliers may require less inventory protection than chemicals available from only a small number of producers.
Finally, establish a regular review process. If manufacturing activity continues to improve, procurement teams can adjust purchasing volumes based on actual order trends rather than relying solely on forecasts.
The ACC expects the US industrial recovery to broaden in 2027, with 15 of the 20 key chemistry-consuming industries projected to expand. It also forecasts US chemical production volumes to increase 1.5% in 2027, with specialty chemical output expected to rebound 2.7%.
For pharmaceutical-adjacent suppliers, this creates a potentially stronger medium-term demand environment. The combination of healthcare growth and broader industrial expansion could support higher requirements for selected specialty chemicals and intermediates.
Buyers can use 2026 to strengthen supplier relationships and improve visibility before broader growth potentially develops in 2027.
The focus should remain on qualified supply, competitive landed costs and dependable delivery rather than simply increasing inventory.
The ACC's 1.3% US industrial production forecast for 2026 points to modest improvement in manufacturing activity rather than a broad industrial boom. Pharmaceuticals and healthcare-related specialty chemicals stand out as areas with stronger growth prospects, creating selective opportunities for chemical producers, traders and suppliers.
For procurement teams, the most important takeaway is that demand conditions are becoming more favorable but remain uneven. Buyers should track product-specific demand, supplier capacity and lead times while maintaining alternative sourcing options for critical materials.
A measured recovery can still create meaningful opportunities when it occurs in markets with specialized products and strict qualification requirements. Companies that build supplier visibility now will be better positioned to respond if healthcare-related chemical demand strengthens further in 2027.
Featured Product
Found this useful?
Continue Reading
Park Systems' NSS Korea expanded beyond AFM into nano-IR, optical measurement and AI-driven characterization. These advances could eventually support pharmaceutical formulation and nanoparticle research.
Dow's potential exit from its Saudi Aramco chemicals partnership is putting attention on the future of petrochemical feedstock and specialty chemical supply. Pharma-adjacent buyers should watch sourcing, production continuity and regional supply risks.
New emissions modeling across 81 chemicals highlights the upstream carbon burden of petrochemical production. For pharma buyers, the findings sharpen attention on solvents, intermediates and supplier emissions
